Showing 26–50 of 102 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Minakshi P, Ghosh M, Brar B, Kumar R, Lambe UP, et al.
… on developments regarding nanoparticle-based therapeutics, vaccines and diagnostic methods developed or under pipeline with their potential benefits and limitations to combat mycobacterial diseases for their successful eradication from the world in future. Results Distinct morph…
Singh Dewhare S
…ntial for the development of more effective drug molecules, vaccines and may help in devising new strategy for containing and eradicating TB.
SushantSatish Mane
… has led to intense research in this field. VPM1002 and MIP vaccines are in their Phase 3 trials to evaluate efficacy and safety for preventing TB disease in healthy household contacts >6 years, of newly diagnosed sputum-positive PTB patients.[8] VPM1002 is being evaluated additi…
Wang DM, Li QF, Zhu M, Wu GH, Li X, et al.
Background Sichuan is a province located in southwestern China, which have a higher incidence of tuberculosis (TB). This study aimed to analyze the epidemiological and clinical characteristics, as well as drug resistance in culture-confirmed children with Tuberculosis meningitis …
Xu Y, Li Q, Zhu M, Wu X, Wang D, et al.
The aim of this study was to investigate the epidemiological characteristics and profile of drug-resistant tuberculosis (DR-TB) among children with TB in Sichuan province of China.From January 2015 to December 2018, microbiological culture-confirmed child TB cases (aged <15 years…
La Manna MP, Orlando V, Tamburini B, Badami GD, Dieli F, et al.
Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus …
Hao L, Ma J, Shi C, Lin X, Zhang Y, et al.
…ods: Recombinant adenovirus type 5 (rAd5) based therapeutic vaccines rAdhGLi and rAdhGLs (rAds) were respectively developed to express intracellular and extracellular granulysin. The ex vivo bactericidal effects of rAdhGLi and rAdhGLs were evaluated on U937 and RAW264.7 cells. Th…
Christoph Lange, Anca Vasiliù, Anna M. Mandalakas
Tuberculosis is the leading cause of death attributed to a single infectious pathogen worldwide. Despite the availability of anti-tuberculosis therapies for more than half a century, the number of people affected by tuberculosis reached a historical peak in 2021.1WHOGlobal tuberc…
Chin KL, Anibarro L, Chang ZY, Palasuberniam P, Mustapha ZA, et al.
Tuberculosis (TB) is the world's second-deadliest infectious disease. Despite the availability of drugs to cure TB, control of TB is hampered by the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). The presence of MDR/XD…
Marimani M, AlOmar SY, Aldahmash B, Ahmad A, Stacey S, et al.
Background Mycobacterium tuberculosis (Mtb) is an airborne pathogenic microorganism that causes tuberculosis (TB). This pathogen invades lung tissues causing pulmonary infections and disseminates into other host organs. The Bacillus Calmette-Guérin (BCG) vaccine is employed to pr…
Swinkels HM, Jilani TN, Tobin EH
…ics. Researchers are developing promising candidates for TB vaccines that can prevent the progression to TB disease. In the United States (US), the TB Centers of Excellence provide readily available expert advice to clinicians. Civil societies, patients, stakeholders, and advocac…
Christoph Lange, Keertan Dheda, Dumitru Chesov, Anna M. Mandalakas, Zarir Udwadia, et al.
It is obvious that more efforts are needed, both in research and development and in implementation, to reduce the drug-resistant tuberculosis epidemic.1Lange C Dheda K Chesov D Mandalakas AM Udwadia Z Horsburgh Jr, CR Management of drug-resistant tuberculosis.Lancet. 2019; 394: 9…
Saima Abid
Antimicrobial resistance (AMR) is a growing public health threat. Resistant microorganisms (i.e. bacteria, viruses and some parasites) through genetic mutations become too strong that they become resistant to the antimicrobials (i.e. antibiotics, antivirals and antimalarial) over…
Tasmin Nazim
…happening after covid‐19 we must work on drug discovery and vaccines to prevent TB from spreading. Objective This work is done on mycobacterium tuberculosis, the causative agent of tuberculosis, using laboratory experiments and computational biological tools to characterize methy…
Ameya D. Bendre, Pooja Singh, Swati Jaiswal
…athogenesis, developing new drugs and treatments, advancing vaccines and diagnostics, exploring innovative approaches for multidrug- and extensively drug-resistant TB, and investigating the molecular and genetic factors that influence mycobacterial responses to therapy, all to im…
В. Н. Даниленко
…cluding virulence inhibitors; third, genetically engineered vaccines, the development of which will account for the existing negative international experience and new scientific approaches, including those proposed in Russia; and, fourth, a new class of adjuvants for vaccines bas…
Kenneth W Foreman, Hui-Chen Foreman
Tuberculosis (TB), primarily caused by(Mtb), remains a leading cause of infectious disease mortality worldwide. Global TB control efforts face several hurdles, including the lack of a broadly effective vaccine, limited sensitivity of current diagnostics, particularly for paucibac…
Christoph Lange, MD, PhD
It is a single-center, observational, prospective cohort study recruiting patients hospitalized at the multidrug-resistant tuberculosis ward at Marius Nasta Institute. This project aims to improve the individual patient management and TB treatment outcomes, especially for patient…
Emmama Jamil, Muhammad Majid Aziz, Afreenish Amir, Brian Godman, Stephen M Campbell, et al.
**BACKGROUND/OBJECTIVES:** Community-acquired pneumonia (CAP) imposes a significant health burden among low- and middle-income countries. The burden is exacerbated by antimicrobial resistance (AMR), often due to inappropriate antibiotic agent use and gaps in antimicrobial steward…
Rojano B, Caminero JA, Hayek M
…-of-care testing, rapid detection of drug resistance, novel vaccines, and new prophylaxis and treatment regimens (particularly for MDR and XDR TB). The ultimate objective of those programs is to develop highly effective drug regimens that can achieve high cure rates regardless of…
Ke Hao, Lihong Fan
…sistant tuberculosis. Host-targeted therapy and therapeutic vaccines are new directions for research into TB adjuvant therapy.
Cynthia R. Giver, Pamela A. Shaw, Helen A. Fletcher, Deepak Kaushal, Garcia Pamela, et al.
Background: With existing anti-tubercular therapies, treatment success rates for multi- and extensively-drug resistant tuberculosis (MDR-TB, XDR-TB) are dismal, highlighting the urgent need for new drugs. Ratios of myeloid to lymphoid cells are important predictors of TB disease …
Yadav S
…d availability of reasonably priced drugs, diagnostics, and vaccines for illnesses with widespread outbreaks in nations with limited resources. While patent protection is vital for stimulating innovation, mechanisms to ensure global accessibility to essential medications remain i…
Faheem I, Nagaraja V
Tuberculosis (TB) continues to be a major cause of death worldwide despite having an effective combinatorial therapeutic regimen and vaccine. Being one of the most successful human pathogens, Mycobacterium tuberculosis retains the ability to adapt to diverse intracellular and ext…
Xu X, Dong B, Peng L, Gao C, He Z, et al.
Mycobacterium tuberculosis possesses a dynamic cell envelope, which consists of a peptidoglycan layer, a mycolic acid layer, and an arabinogalactan polysaccharide. This envelope possesses a highly complex and unique structure representing a barrier that protects and assists the g…